|
ATE513843T1
(de)
*
|
2002-09-25 |
2011-07-15 |
Univ Massachusetts |
Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
|
|
CN104212799B
(zh)
|
2008-10-15 |
2018-11-23 |
Ionis制药公司 |
因子11表达的调节
|
|
HRP20150796T1
(hr)
|
2008-10-20 |
2015-09-11 |
Alnylam Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije transtiretina
|
|
CA2818662C
(en)
|
2010-10-22 |
2021-07-06 |
Sungkyunkwan University Foundation For Corporate Collaboration |
Nucleic acid molecule inducing rna interference, and uses thereof
|
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
CN106434665B
(zh)
|
2011-06-30 |
2021-06-08 |
箭头药业股份有限公司 |
用于抑制乙型肝炎病毒的基因表达的组合物和方法
|
|
EP2751270B1
(en)
|
2011-08-29 |
2018-08-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
MY167390A
(en)
|
2011-11-18 |
2018-08-16 |
Alnylam Pharmaceuticals Inc |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
KR20250133484A
(ko)
*
|
2011-11-18 |
2025-09-05 |
알닐람 파마슈티칼스 인코포레이티드 |
변형된 RNAi 제제
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
EP3514236A1
(en)
*
|
2012-05-22 |
2019-07-24 |
Olix Pharmaceuticals, Inc. |
Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
|
|
JP6208228B2
(ja)
|
2012-06-21 |
2017-10-04 |
ミラゲン セラピューティクス, インコーポレイテッド |
ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
|
|
DK2879718T3
(da)
*
|
2012-08-06 |
2023-06-19 |
Alnylam Pharmaceuticals Inc |
Proces til fremstilling af kulhydratkonjugerede RNA-stoffer
|
|
US9879041B2
(en)
|
2012-11-28 |
2018-01-30 |
Victoria Link Limited |
Saccharide dendritic cluster compounds as inhibitors of BACE-1
|
|
TW201446791A
(zh)
*
|
2013-05-01 |
2014-12-16 |
Regulus Therapeutics Inc |
用於調節mir-122之微小rna化合物及方法
|
|
KR102482890B1
(ko)
*
|
2013-05-01 |
2022-12-30 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
|
|
AU2014284152B2
(en)
|
2013-06-21 |
2020-01-23 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
WO2015085158A1
(en)
|
2013-12-06 |
2015-06-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
|
|
KR102344559B1
(ko)
|
2013-12-12 |
2021-12-31 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 iRNA 조성물 및 이의 이용 방법
|
|
WO2015105083A1
(ja)
*
|
2014-01-07 |
2015-07-16 |
塩野義製薬株式会社 |
アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
|
|
WO2015143246A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
MY192634A
(en)
|
2014-04-01 |
2022-08-29 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
CN106232125B
(zh)
|
2014-05-01 |
2020-10-16 |
Ionis制药公司 |
用于调节pkk表达的组合物和方法
|
|
SI3137605T1
(sl)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
|
|
US10098959B2
(en)
|
2014-05-01 |
2018-10-16 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
CN110903337A
(zh)
*
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
PE20170010A1
(es)
|
2014-05-01 |
2017-03-04 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
SG11201704660YA
(en)
|
2014-12-08 |
2017-07-28 |
Berg Llc |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
|
CN107532162A
(zh)
|
2014-12-12 |
2018-01-02 |
托德·M·伍尔夫 |
用于利用寡核苷酸编辑细胞中核酸的组合物和方法
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
EP3247716A4
(en)
|
2015-01-20 |
2018-10-17 |
Miragen Therapeutics, Inc. |
Mir-92 inhibitors and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
JP6667179B2
(ja)
|
2015-03-24 |
2020-03-18 |
国立大学法人岐阜大学 |
オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
PE20180800A1
(es)
|
2015-07-10 |
2018-05-09 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
|
|
US20180193471A1
(en)
*
|
2015-07-16 |
2018-07-12 |
Kyowa Hakko Kirin Co., Ltd. |
ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE
|
|
ES2842300T3
(es)
|
2015-07-31 |
2021-07-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
|
WO2017030973A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
TW201723176A
(zh)
|
2015-09-24 |
2017-07-01 |
Ionis製藥公司 |
Kras表現之調節劑
|
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
|
CA2998898A1
(en)
|
2015-10-08 |
2017-04-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
DK4119569T3
(da)
|
2015-11-06 |
2024-08-12 |
Ionis Pharmaceuticals Inc |
Konjugerede antisense-forbindelser til anvendelse i behandling
|
|
CA2999341A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
EP3377630A4
(en)
|
2015-11-16 |
2020-01-01 |
Olix Pharmaceuticals, Inc. |
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
EP3397288A4
(en)
|
2015-12-31 |
2019-09-11 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING ATAXIN-2 EXPRESSION
|
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING LRRK2 EXPRESSION
|
|
WO2017134526A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
|
|
CN108779463B
(zh)
|
2016-02-02 |
2022-05-24 |
奥利克斯医药有限公司 |
使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘
|
|
CN109069529B
(zh)
|
2016-03-07 |
2021-08-20 |
箭头药业股份有限公司 |
用于治疗性化合物的靶向配体
|
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
|
WO2017178883A2
(en)
|
2016-04-11 |
2017-10-19 |
Olix Pharmaceuticals, Inc. |
Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
|
|
CA3022319A1
(en)
|
2016-05-06 |
2017-11-09 |
Tod M. Woolf |
Improved methods for genome editing with and without programmable nucleases
|
|
EP3469073B1
(en)
|
2016-06-09 |
2024-01-10 |
Centre National de la Recherche Scientifique (CNRS) |
Raav with chemically modified capsid
|
|
WO2017219017A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CN109462981B
(zh)
|
2016-09-02 |
2023-07-07 |
箭头药业股份有限公司 |
靶向配体
|
|
CN109661233A
(zh)
|
2016-10-06 |
2019-04-19 |
Ionis 制药公司 |
缀合低聚化合物的方法
|
|
US10131911B2
(en)
|
2016-11-07 |
2018-11-20 |
nanoSUR LLC |
Post-transcriptionally chemically modified double strand RNAs
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
US11591600B2
(en)
|
2017-02-10 |
2023-02-28 |
OliX Pharmaceuticals. Inc. |
Long double-stranded RNA for RNA interference
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
EP3603648B1
(en)
|
2017-03-29 |
2025-09-17 |
Shionogi & Co., Ltd |
Complex of nucleic acid medicine and multibranched lipid
|
|
LT3607069T
(lt)
|
2017-04-05 |
2023-01-10 |
Silence Therapeutics Gmbh |
Produktai ir kompozicijos
|
|
WO2018223056A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018223081A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
MA50267A
(fr)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals Inc |
Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
|
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
WO2019105418A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
US11414665B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
KR102834361B1
(ko)
|
2017-12-01 |
2025-07-17 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
JP7348185B2
(ja)
|
2017-12-21 |
2023-09-20 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
キラル富化二本鎖rna剤
|
|
CA3087106A1
(en)
|
2017-12-29 |
2019-07-04 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
CN115976028B
(zh)
|
2018-03-09 |
2025-03-25 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
US11365416B2
(en)
|
2018-04-11 |
2022-06-21 |
Ionis Pharmaceuticals, Inc. |
Modulators of EZH2 expression
|
|
SG11202010910QA
(en)
|
2018-05-07 |
2020-12-30 |
Alnylam Pharmaceuticals Inc |
Extrahepatic delivery
|
|
CN112400020B
(zh)
|
2018-05-08 |
2024-11-19 |
莱古路斯治疗法股份有限公司 |
作为具有hcv抗病毒活性与降低的高胆红素血症副作用的mir-122抑制剂的galnac缀合的经修饰的寡核苷酸
|
|
WO2019217708A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
US20210355497A1
(en)
|
2018-05-09 |
2021-11-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fxi expression
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2019241648A1
(en)
|
2018-06-14 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing stmn2 expression
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
EP3833763A4
(en)
|
2018-08-10 |
2023-07-19 |
University of Massachusetts |
MODIFIED OLIGONUCLEOTIDES FOR TARGETING SNPS
|
|
JP2021533800A
(ja)
|
2018-08-21 |
2021-12-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. |
核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
|
|
US11279930B2
(en)
|
2018-08-23 |
2022-03-22 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
CN111655297A
(zh)
|
2018-09-30 |
2020-09-11 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
WO2020102630A1
(en)
|
2018-11-15 |
2020-05-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf5 expression
|
|
MY205095A
(en)
|
2018-11-21 |
2024-10-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing prion expression
|
|
UA128236C2
(uk)
|
2018-12-21 |
2024-05-15 |
Айоніс Фармасутікалз, Інк. |
Модулятори експресії hsd17b13
|
|
JP2022523467A
(ja)
*
|
2019-01-18 |
2022-04-25 |
ユニバーシティ・オブ・マサチューセッツ |
動的な薬物動態を修飾するアンカー
|
|
US11214803B2
(en)
|
2019-01-31 |
2022-01-04 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
|
KR20210134686A
(ko)
|
2019-02-27 |
2021-11-10 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Malat1 발현의 조절인자
|
|
CN117431244A
(zh)
|
2019-03-29 |
2024-01-23 |
Ionis制药公司 |
用于调节ube3a-ats的化合物和方法
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
EP4660307A2
(en)
|
2019-07-26 |
2025-12-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
US20220267778A1
(en)
|
2019-07-30 |
2022-08-25 |
Shionogi & Co., Ltd. |
Nucleic acid drug targeting murf1
|
|
CA3150715A1
(en)
|
2019-09-10 |
2021-03-18 |
Makoto Koizumi |
Conjugate of galnac-oligonucleotide for delivery to liver and manufacturing method thereof
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
JP7757277B2
(ja)
|
2019-10-14 |
2025-10-21 |
アストラゼネカ・アクチエボラーグ |
Pnpla3発現のモジュレーター
|
|
JP7676377B2
(ja)
|
2019-10-22 |
2025-05-14 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分C3 iRNA組成物およびその使用方法
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
AR121446A1
(es)
|
2020-02-28 |
2022-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
MX2022011806A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
|
|
JP2023520764A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用
|
|
EP4138858A4
(en)
|
2020-04-21 |
2024-07-03 |
Flagship Pioneering, Inc. |
BIFUNCTIONAL MOLECULES AND METHODS OF USE THEREOF
|
|
JP7738573B2
(ja)
|
2020-05-01 |
2025-09-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Atxn1を調節するための化合物及び方法
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN116096899A
(zh)
|
2020-06-29 |
2023-05-09 |
Ionis制药公司 |
调节plp1的化合物和方法
|
|
UY39344A
(es)
|
2020-07-28 |
2022-02-25 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de app
|
|
CA3186935A1
(en)
|
2020-08-07 |
2022-02-10 |
Paymaan JAFAR-NEJAD |
Compounds and methods for modulating scn2a
|
|
TW202227101A
(zh)
|
2020-11-18 |
2022-07-16 |
美商Ionis製藥公司 |
用於調節血管收縮素原表現之化合物及方法
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
TW202242111A
(zh)
|
2020-12-18 |
2022-11-01 |
美商Ionis製藥公司 |
用於調節因子xii之化合物及方法
|
|
US20240058279A1
(en)
|
2020-12-21 |
2024-02-22 |
Flagship Pioneering Innovations V, Inc. |
Use of cell turnover factors for increasing tissue regeneration
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
KR20230137295A
(ko)
*
|
2021-01-28 |
2023-10-04 |
난징 챔피언 바이오테크놀로지 컴퍼니 리미티드 |
접합체 및 이의 용도
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
US20230059578A1
(en)
|
2021-04-06 |
2023-02-23 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
|
EP4320443A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for the prognosis of breast cancer progression
|
|
CA3214819A1
(en)
|
2021-04-06 |
2022-10-13 |
Guisong WANG |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
MX2023015230A
(es)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de ifnar1.
|
|
EP4359539A4
(en)
|
2021-06-23 |
2025-05-14 |
University Of Massachusetts |
ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS OPTIMIZED FOR THE TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
CN115920065A
(zh)
*
|
2021-08-02 |
2023-04-07 |
南方科技大学 |
一种可靶向去唾液酸糖蛋白受体的配体及其缀合物与用途
|
|
MX2024001194A
(es)
|
2021-08-03 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
|
|
CA3233755A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
EP4423273A1
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
EP4430187A2
(en)
|
2021-11-10 |
2024-09-18 |
University of Rochester |
Antisense oligonucleotides for modifying protein expression
|
|
CN116917477B
(zh)
*
|
2022-01-30 |
2024-04-09 |
大睿生物医药科技(上海)有限公司 |
含有n-乙酰半乳糖胺的靶向配体
|
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
|
WO2023178144A2
(en)
|
2022-03-16 |
2023-09-21 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
|
AU2023245603A1
(en)
|
2022-03-28 |
2024-11-07 |
Empirico Inc. |
Modified oligonucleotides
|
|
CN117264950A
(zh)
*
|
2022-07-07 |
2023-12-22 |
北京福元医药股份有限公司 |
用于抑制c5基因表达的双链核糖核酸及其修饰物、缀合物和用途
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
KR20250075637A
(ko)
|
2022-09-23 |
2025-05-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Mecp2 발현을 감소시키기 위한 화합물 및 방법(compounds and methods for reducing mecp2 expression)
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
TW202448484A
(zh)
|
2023-04-20 |
2024-12-16 |
美商雅迪克斯製藥公司 |
Mapt調節組合物及其使用方法
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
WO2024249328A2
(en)
|
2023-05-26 |
2024-12-05 |
Adarx Pharmaceuticals, Inc. |
Sod1-modulating compositions and methods of use thereof
|
|
TW202506137A
(zh)
|
2023-06-20 |
2025-02-16 |
美商雅迪克斯製藥公司 |
Lrrk2調節組合物及其使用方法
|
|
GB202314724D0
(en)
|
2023-09-26 |
2023-11-08 |
Astrazeneca Ab |
compounds and methods for reducing psd3 expression
|
|
WO2025196505A2
(en)
|
2024-03-22 |
2025-09-25 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
|